当前位置:科学网首页 > 小柯机器人 >详情
中国科学家探讨大蒜对胃癌的预防作用
作者:小柯机器人 发布时间:2019/9/12 16:27:09

北京大学肿瘤医院潘凯枫教授课题组探讨了幽门螺杆菌治疗、补充维生素和大蒜对胃癌的预防作用。2019年9月11日,《英国医学杂志》在线发表了这项成果。

课题组在胃癌高危区招募了3365名居民,其中2258名幽门螺杆菌抗体阳性的居民被随机分配到幽门螺杆菌治疗组(阿莫西林与奥美拉唑联合治疗2周)、维生素补充组(维C、E和硒,持续7.3年)、大蒜补充组(大蒜提取液和油,持续7.3年)或安慰剂组;1107名幽门螺杆菌抗体阴性的居民被随机分配到维生素补充组、大蒜补充组或安慰剂组。

1995-2017年间共发生胃癌151例,死亡94例。幽门螺杆菌治疗对胃癌发生率的保护作用持续了22年,优势比为0.48。在补充维生素但不补充大蒜的参与者中,胃癌发病率显著下降。所有三种干预措施均显著降低了胃癌死亡率:幽门螺杆菌治疗的完全校正风险比为0.62,补充维生素为0.48,补充大蒜为0.66。

幽门螺杆菌治疗和补充维生素对胃癌发病率和死亡率的影响早有报道,而补充维生素和大蒜对胃癌发病率的影响则近期才有所报道。干预措施与其他癌症或心血管疾病之间不相关。

综上,幽门螺杆菌治疗2周、补充维生素或大蒜7年以上,均可显著降低22年以上胃癌死亡风险。幽门螺杆菌治疗和补充维生素可显著降低胃癌的发病率。

更多阅读

潘凯枫,教授、研究员,博士生导师,现任北京大学肿瘤医院副院长兼流行病学研究室主任。目前主要从事胃癌分子流行病学研究,包括遗传学和表观遗传学研究,胃癌预警、早诊相关标志物的筛选及干预相关分子机制研究。(据北京大学肿瘤医院

附:英文原文

Title:Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial

Author: Wen-Qing Li, professor, Jing-Yu Zhang, PhD candidate, Jun-Ling Ma, associate professor, Zhe-Xuan Li, assistant professor, Lian Zhang, professor, Yang Zhang, associate professor, Yang Guo, PhD candidate, Tong Zhou, technician, Ji-You Li, professor, Lin Shen, professor, Wei-Dong Liu, chief physician, Zhong-Xiang Han, associate chief physician, William J Blot, professor, Mitchell H Gail, senior investigator, Kai-Feng Pan, professor, Wei-Cheng You, professor

Issue&Volume: 2019-09-11

Abstract:

Objective To assess the effects of Helicobacter pylori treatment, vitamin supplementation, and garlic supplementation in the prevention of gastric cancer.

Design Blinded randomized placebo controlled trial.

Setting Linqu County, Shandong province, China.

Participants 3365 residents of a high risk region for gastric cancer. 2258 participants seropositive for antibodies to H pylori were randomly assigned to H pylori treatment, vitamin supplementation, garlic supplementation, or their placebos in a 2×2×2 factorial design, and 1107 H pylori seronegative participants were randomly assigned to vitamin supplementation, garlic supplementation, or their placebos in a 2×2 factorial design.

Interventions H pylori treatment with amoxicillin and omeprazole for two weeks; vitamin (C, E, and selenium) and garlic (extract and oil) supplementation for 7.3 years (1995-2003).

Main outcome measures Primary outcomes were cumulative incidence of gastric cancer identified through scheduled gastroscopies and active clinical follow-up through 2017, and deaths due to gastric cancer ascertained from death certificates and hospital records. Secondary outcomes were associations with other cause specific deaths, including cancers or cardiovascular disease.

Results 151 incident cases of gastric cancer and 94 deaths from gastric cancer were identified during 1995-2017. A protective effect of H pylori treatment on gastric cancer incidence persisted 22 years post-intervention (odds ratio 0.48, 95% confidence interval 0.32 to 0.71). Incidence decreased significantly with vitamin supplementation but not with garlic supplementation (0.64, 0.46 to 0.91 and 0.81, 0.57 to 1.13, respectively). All three interventions showed significant reductions in gastric cancer mortality: fully adjusted hazard ratio for H pylori treatment was 0.62 (95% confidence interval 0.39 to 0.99), for vitamin supplementation was 0.48 (0.31 to 0.75), and for garlic supplementation was 0.66 (0.43 to 1.00). Effects of H pylori treatment on both gastric cancer incidence and mortality and of vitamin supplementation on gastric cancer mortality appeared early, but the effects of vitamin supplementation on gastric cancer incidence and of garlic supplementation only appeared later. No statistically significant associations were found between interventions and other cancers or cardiovascular disease.

Conclusions H pylori treatment for two weeks and vitamin or garlic supplementation for seven years were associated with a statistically significant reduced risk of death due to gastric cancer for more than 22 years. H pylori treatment and vitamin supplementation were also associated with a statistically significantly reduced incidence of gastric cancer.

DOI:10.1136/bmj.l5016

Source:https://www.bmj.com/content/366/bmj.l5016

期刊信息

BMJ-British Medical Journal:《英国医学杂志》,创刊于1840年。隶属于BMJ出版集团,最新IF:27.604
官方网址:http://www.bmj.com/
投稿链接:https://mc.manuscriptcentral.com/bmj